Jiwoong Park

Jiwoong Park

Auto-generated profile, based on publicly available information

Jiwoong Park

Division of Bone and Mineral Diseases, Department of Medicine, Washington University School of Medicine, BJC Institute of Health, 425 S. Euclid Ave., St. Louis, MO 63110, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LSLauren Surface
Lauren Surface
DBDamon T. Burrow
Damon T. Burrow
JLJinmei Li
Jinmei Li
JPJiwoong Park
Jiwoong Park
SKSandeep Kumar
Sandeep Kumar
TPTimothy R. Peterson
Timothy R. Peterson
ATRAID is essential for responses to the commonly prescribed osteoporosis drugs nitrogen-containing bisphosphonates.

14 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SKSandeep Kumar
Sandeep Kumar
JLJinmei Li
Jinmei Li
JPJiwoong Park
Jiwoong Park
SHSydney K. Hart
Sydney K. Hart
NSNiki J. Song
Niki J. Song
TPTim R. Peterson
Tim R. Peterson
Chloroquine is an anti-malarial and immunosuppressant drug that has cationic amphipathic chemical properties. We performed genome-wide screens in human cells with chloroquine and several other widely used cationic amphipathic drugs (CADs) including the anti-depressants, sertraline (Zoloft) and fluoxetine (Prozac), the analgesic nortriptyline (Pamelor), the anti-arrhythmic amiodarone (Cordarone), and the anti-hypertensive verapamil (Calan) to characterize their molecular similarities and differences. Despite CADs having different disease indications but consistent with them sharing key chemical properties, we found CADs to have remarkably similar phenotypic profiles compared with non-CADs we and others have previously screened (1–5). The most significant genetic interaction for all CADs was the initiating step in sphingolipid biosynthesis catalyzed by serine palmitoyltransferase (SPT). A comparison of genome-wide screens performed with diverse pathogens from viruses, bacteria, plants, and parasites including Ebola (6), adeno-associated virus AAV2 (7), HIV (8), Rotavirus (9), Influenza A (10), Zika virus (11), Picornavirus (12), Exotoxin A (13), Cholera toxin (14), Type III secretion system and Shiga toxin (15, 16), Ricin toxin (17), and Toxoplasma gondii (18) showed SPT as a top common host factor and 80% overlap overall in top hits specifically with CADs. Potential sphingolipid-mediated mechanisms for the host response- and virulence-modulating effects of CADs involve autophagy and SERPINE1/PAI-1 (plasminogen activator inhibitor-1). Chloroquine has recently shown potential as an anti-viral agent for the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease (19, 20). Our study demonstrates that numerous readily available drugs molecularly function highly similar to chloroquine, which suggests they might be considered for further pre-clinical investigation in the context of SARS-CoV-2. More generally, our work suggests the diverse pathogen mitigating potential of drugs that inhibit host sphingolipid biosynthesis such as CADs. Brief Summary: Our study demonstrates that numerous readily available drugs molecularly function highly similar to chloroquine, which suggests they might be considered for further pre-clinical investigation in the context of SARS-CoV-2.

5 December 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
NJNicholas C. Jacobs
Nicholas C. Jacobs
JPJiwoong Park
Jiwoong Park
NSNancy L. Saccone
Nancy L. Saccone
TPTimothy R. Peterson
Timothy R. Peterson
Moore’s law states that computers get faster and less expensive over time. In contrast in biopharma, there is the reverse spelling, Eroom’s law, which states that drug discovery is getting slower and costing more money every year. Herein, we propose a solution to this problem. We put forth a consensus algorithm for inexpensively and rapidly prioritizing new factors of interest (e.g., a gene or drug) in human disease research. Specifically, we argue for synthetic interaction testing in mammalian cells using cell fitness – which reflect changes in cell number that could be due many effects – as a readout to judge the potential of the new factor. That is, if we combine perturbing a known factor with perturbing an unknown factor and they produce a synergistic, i.e., multiplicative rather than additive cell fitness phenotype, this justifies proceeding with the unknown gene/drug in more complex models where the known perturbation is already validated. This recommendation is backed by the following evidence we demonstrate herein: 1) human genes currently known to be important to cell fitness involve nearly all classifications of cellular and molecular processes; 2) Nearly all human genes important in cancer – a disease defined by altered cell number – are also important in other common diseases; 3) Many drugs affect a patient’s condition and the fitness of their cells comparably. We provide proof of concept of the Omniphenotype model using the widely used osteoporosis drug, bisphosphonates, implicating its mechanism of action (MoA) genes, ATRAID, SLC37A3, and FDPS, as potential gerotargets for neurodegenerative conditions. Taken together, these findings suggest cell fitness could be a broadly applicable phenotype for understanding gene, disease, and drug function. Measuring cell fitness is robust and requires little time and money. These are features that have long been capitalized on by pioneers using model organisms that we hope more mammalian biologists will recognize. Short summary: Cell fitness is a biological hash function that enables interoperability of biomedical data.